Does treatment sequence affect outcomes in patients with metaplastic breast cancer?

We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall su...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2021-04, Vol.221 (4), p.701-705
Main Authors: Ladipo, Oluwatomi L., Ren, Yi, Caddell, Keenan B., Sampathkumar, Anuyuga, Almond, Chandra A., Fayanju, Oluwadamilola M.
Format: Article
Language:English
Subjects:
Adjuvant
Adult
Age
Age Factors
Aged
Breast cancer
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Female
Hispanic people
Histology
Humans
Kaplan-Meier Estimate
Medical prognosis
Metaplastic
Middle Aged
Mutation
Neoadjuvant
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Staging
Patients
Prognosis
Radiation
Radiotherapy, Adjuvant
Rank tests
Survival
Treatment sequence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353
cites cdi_FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353
container_end_page 705
container_issue 4
container_start_page 701
container_title The American journal of surgery
container_volume 221
creator Ladipo, Oluwatomi L.
Ren, Yi
Caddell, Keenan B.
Sampathkumar, Anuyuga
Almond, Chandra A.
Fayanju, Oluwadamilola M.
description We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p 
doi_str_mv 10.1016/j.amjsurg.2021.01.007
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8134971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961021000052</els_id><sourcerecordid>2511202464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVpabZpf0KLoZdevB19-ePSENJPCPSQ9CxkeZzI2NZWklP67zPLbkPbS0AghJ53NKOHsdccthx49X7c2nlMa7zZChB8C7SgfsI2vKnbkjeNfMo2ACDKtuJwwl6kNNKRcyWfsxMptagkiA27-hgwFTmizTMuuUj4c8XFYWGHAV0uwppdmAnxS7Gz2ROTil8-3xYzZrubbMreFR3lUy6cpWQ8e8meDXZK-Oq4n7Ifnz9dX3wtL79_-XZxflk61epcDtqiVMpZkGIAtH2nXaMBpXROt1hJIXrRYaNVXUHXVbXVEobado3rtZNanrIPh7q7tZuxd9RbtJPZRT_b-NsE682_N4u_NTfhzjRcqrbmVODdsUAMNHbKZvbJ4TTZBcOajFCN1rxVAIS-_Q8dwxoXGs8IzTk5UJUiSh8oF0NKEYeHZjiYvTYzmqM2s9dmgBbUlHvz9yQPqT-eCDg7AEj_eecxmuT83lPvI2kyffCPPHEP-Lqtew</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2511202464</pqid></control><display><type>article</type><title>Does treatment sequence affect outcomes in patients with metaplastic breast cancer?</title><source>Elsevier</source><creator>Ladipo, Oluwatomi L. ; Ren, Yi ; Caddell, Keenan B. ; Sampathkumar, Anuyuga ; Almond, Chandra A. ; Fayanju, Oluwadamilola M.</creator><creatorcontrib>Ladipo, Oluwatomi L. ; Ren, Yi ; Caddell, Keenan B. ; Sampathkumar, Anuyuga ; Almond, Chandra A. ; Fayanju, Oluwadamilola M.</creatorcontrib><description>We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p &lt; 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs &lt; 50 y). Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence. In our study of metaplastic breast cancer (MBC), an aggressive subtype:Most MBC patients received neoadjuvant (NACT) or adjuvant chemotherapy (ACT).NACT recipients were younger than ACT recipients.NACT and ACT recipients were similar with regards to race and radiation receipt.MBC patients had similar survival regardless of treatment sequence.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2021.01.007</identifier><identifier>PMID: 33526302</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant ; Adult ; Age ; Age Factors ; Aged ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Female ; Hispanic people ; Histology ; Humans ; Kaplan-Meier Estimate ; Medical prognosis ; Metaplastic ; Middle Aged ; Mutation ; Neoadjuvant ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Patients ; Prognosis ; Radiation ; Radiotherapy, Adjuvant ; Rank tests ; Survival ; Treatment sequence</subject><ispartof>The American journal of surgery, 2021-04, Vol.221 (4), p.701-705</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Apr 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353</citedby><cites>FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353</cites><orcidid>0000-0003-2218-9935 ; 0000-0002-0876-975X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33526302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ladipo, Oluwatomi L.</creatorcontrib><creatorcontrib>Ren, Yi</creatorcontrib><creatorcontrib>Caddell, Keenan B.</creatorcontrib><creatorcontrib>Sampathkumar, Anuyuga</creatorcontrib><creatorcontrib>Almond, Chandra A.</creatorcontrib><creatorcontrib>Fayanju, Oluwadamilola M.</creatorcontrib><title>Does treatment sequence affect outcomes in patients with metaplastic breast cancer?</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p &lt; 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs &lt; 50 y). Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence. In our study of metaplastic breast cancer (MBC), an aggressive subtype:Most MBC patients received neoadjuvant (NACT) or adjuvant chemotherapy (ACT).NACT recipients were younger than ACT recipients.NACT and ACT recipients were similar with regards to race and radiation receipt.MBC patients had similar survival regardless of treatment sequence.</description><subject>Adjuvant</subject><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Hispanic people</subject><subject>Histology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Medical prognosis</subject><subject>Metaplastic</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoadjuvant</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiation</subject><subject>Radiotherapy, Adjuvant</subject><subject>Rank tests</subject><subject>Survival</subject><subject>Treatment sequence</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkU1r3DAQhkVpabZpf0KLoZdevB19-ePSENJPCPSQ9CxkeZzI2NZWklP67zPLbkPbS0AghJ53NKOHsdccthx49X7c2nlMa7zZChB8C7SgfsI2vKnbkjeNfMo2ACDKtuJwwl6kNNKRcyWfsxMptagkiA27-hgwFTmizTMuuUj4c8XFYWGHAV0uwppdmAnxS7Gz2ROTil8-3xYzZrubbMreFR3lUy6cpWQ8e8meDXZK-Oq4n7Ifnz9dX3wtL79_-XZxflk61epcDtqiVMpZkGIAtH2nXaMBpXROt1hJIXrRYaNVXUHXVbXVEobado3rtZNanrIPh7q7tZuxd9RbtJPZRT_b-NsE682_N4u_NTfhzjRcqrbmVODdsUAMNHbKZvbJ4TTZBcOajFCN1rxVAIS-_Q8dwxoXGs8IzTk5UJUiSh8oF0NKEYeHZjiYvTYzmqM2s9dmgBbUlHvz9yQPqT-eCDg7AEj_eecxmuT83lPvI2kyffCPPHEP-Lqtew</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Ladipo, Oluwatomi L.</creator><creator>Ren, Yi</creator><creator>Caddell, Keenan B.</creator><creator>Sampathkumar, Anuyuga</creator><creator>Almond, Chandra A.</creator><creator>Fayanju, Oluwadamilola M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2218-9935</orcidid><orcidid>https://orcid.org/0000-0002-0876-975X</orcidid></search><sort><creationdate>20210401</creationdate><title>Does treatment sequence affect outcomes in patients with metaplastic breast cancer?</title><author>Ladipo, Oluwatomi L. ; Ren, Yi ; Caddell, Keenan B. ; Sampathkumar, Anuyuga ; Almond, Chandra A. ; Fayanju, Oluwadamilola M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvant</topic><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Hispanic people</topic><topic>Histology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Medical prognosis</topic><topic>Metaplastic</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoadjuvant</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiation</topic><topic>Radiotherapy, Adjuvant</topic><topic>Rank tests</topic><topic>Survival</topic><topic>Treatment sequence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ladipo, Oluwatomi L.</creatorcontrib><creatorcontrib>Ren, Yi</creatorcontrib><creatorcontrib>Caddell, Keenan B.</creatorcontrib><creatorcontrib>Sampathkumar, Anuyuga</creatorcontrib><creatorcontrib>Almond, Chandra A.</creatorcontrib><creatorcontrib>Fayanju, Oluwadamilola M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ladipo, Oluwatomi L.</au><au>Ren, Yi</au><au>Caddell, Keenan B.</au><au>Sampathkumar, Anuyuga</au><au>Almond, Chandra A.</au><au>Fayanju, Oluwadamilola M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does treatment sequence affect outcomes in patients with metaplastic breast cancer?</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>221</volume><issue>4</issue><spage>701</spage><epage>705</epage><pages>701-705</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p &lt; 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs &lt; 50 y). Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence. In our study of metaplastic breast cancer (MBC), an aggressive subtype:Most MBC patients received neoadjuvant (NACT) or adjuvant chemotherapy (ACT).NACT recipients were younger than ACT recipients.NACT and ACT recipients were similar with regards to race and radiation receipt.MBC patients had similar survival regardless of treatment sequence.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33526302</pmid><doi>10.1016/j.amjsurg.2021.01.007</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2218-9935</orcidid><orcidid>https://orcid.org/0000-0002-0876-975X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9610
ispartof The American journal of surgery, 2021-04, Vol.221 (4), p.701-705
issn 0002-9610
1879-1883
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8134971
source Elsevier
subjects Adjuvant
Adult
Age
Age Factors
Aged
Breast cancer
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Female
Hispanic people
Histology
Humans
Kaplan-Meier Estimate
Medical prognosis
Metaplastic
Middle Aged
Mutation
Neoadjuvant
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Staging
Patients
Prognosis
Radiation
Radiotherapy, Adjuvant
Rank tests
Survival
Treatment sequence
title Does treatment sequence affect outcomes in patients with metaplastic breast cancer?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A52%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20treatment%20sequence%20affect%20outcomes%20in%20patients%20with%20metaplastic%20breast%20cancer?&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Ladipo,%20Oluwatomi%20L.&rft.date=2021-04-01&rft.volume=221&rft.issue=4&rft.spage=701&rft.epage=705&rft.pages=701-705&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2021.01.007&rft_dat=%3Cproquest_pubme%3E2511202464%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c495t-f5ae344ca032f0eadb5c850e33cc59e6322d2be854760bb67a530f7ab8cd5c353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2511202464&rft_id=info:pmid/33526302&rfr_iscdi=true